{"id":57,"date":"2021-11-04T08:00:00","date_gmt":"2021-11-04T08:00:00","guid":{"rendered":"https:\/\/dalriadatx.com\/2022\/04\/27\/blog-post-title-7\/"},"modified":"2024-04-07T17:00:22","modified_gmt":"2024-04-07T21:00:22","slug":"dalriada-celebrates-client-dunad-therapeutics-billion-dollar-collaboration-with-novartis","status":"publish","type":"post","link":"https:\/\/dalriadatx.com\/post\/dalriada-celebrates-client-dunad-therapeutics-billion-dollar-collaboration-with-novartis\/","title":{"rendered":"Dalriada Celebrates Client Dunad Therapeutics Billion Dollar Collaboration with Novartis"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"57\" class=\"elementor elementor-57\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-b0b62b4 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"b0b62b4\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-48ec2f6 jltma-glass-effect-no\" data-id=\"48ec2f6\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8571d95 jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"8571d95\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.20.0 - 26-03-2024 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\tDalriada has worked with Dunad since its inception to support the development of its novel small molecule protein degradation modality\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-4fb09bc elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"4fb09bc\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7348772 jltma-glass-effect-no\" data-id=\"7348772\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-37a1281 jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"37a1281\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p><strong>Toronto, ON, November 4, 2021<\/strong> \u2013 Dalriada is pleased to congratulate Dunad Therapeutics on its strategic collaboration and license agreement with Novartis potentially worth $1.35 billion, to generate orally bioavailable covalent and protein degrading small molecule drugs. This leading-edge technology has the potential to deliver next-generation therapeutics with advantages over traditional drugs against a wide range of diseases by unlocking access to disease-causing and often undruggable targets.<\/p>\n<p>Since its inception Dunad\u2019s R&amp;D has been supported by Dalriada, a contract research organization to enable the development of their novel therapeutic modality thatuses mono-valent small molecules to induce selective degradation of proteins via direct modification of the target.<\/p>\n<p><em>\u201cWe are very pleased to see the impact and application of Dunad\u2019s technology amplified through the collaboration with Novartis,\u201d<\/em> says Dr. Charlie Younger, Chief Operating Officer, Dalriada. <em>\u201cIt takes an agile and innovative team to advance a novel therapeutic modality. We\u2019ve had the privilege of supporting Dunad to rapidly scale and further validate their platform technology, and to continue supporting the quick advancement of their pipeline.\u201d<\/em><\/p>\n<p>Dunad\u2019s unique platform offers a target-class agnostic mechanism of action that is clearly differentiated from other targeted protein degradation technologies. As part of their Turn-key\u2122 model, Dalriada has been providing integrated drug discovery support for Dunad across medicinal chemistry, biophysics, cell and molecular biology and proteomics.<\/p>\n<p><em>\u201cDalriada has provided the perfect model to support a rapidly growing company like Dunad. To scale up at the pace we have, proactive communication and quick turn-around times from resource deployment to the design-make-test-analyse cycles are critical,\u201d<\/em> says Dr. Graham Simpson, Senior Vice President Drug Discovery, Dunad. <em>\u201cDalriada has consistently invested in the science and focused on meeting our objectives. Their team has become a most trusted partner for Dunad.\u201d <\/em><\/p>\n<p><em>\u201cWe consider the unique science and needs of each of our partners to create a highly tailored approach that includes everything from custom assays to full program design,\u201d<\/em> says Jeff O\u2019Meara, Vice President Drug Discovery, Dalriada. <em>\u201cIt\u2019s great to see that our team\u2019s focus on the fastest possible turn-around times in the design-make-test-analyse cycle is achieving significant outcomes for our clients.\u201d <\/em><\/p>\n<p><em>\u201cDrug discovery and the biotech industry are in a very exciting, disruptive period. As we shift towards novel therapeutic modalities, we are paving the way to better treat complex diseases and modulate previously inaccessible targets,\u201d<\/em> adds Younger. <em>\u201cUnchartered territory requires a new way of thinking that isn\u2019t one size fits all. Dalriada understands that to break new ground in the evolving drug discovery space, biotech companies need tailored, comprehensive support right from the start to most rapidly and effectively advance their technologies and pipelines.\u201d<\/em><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-4745569 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"4745569\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e47bdb3 jltma-glass-effect-no\" data-id=\"e47bdb3\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8fde2c5 jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"8fde2c5\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<h2>Dalriada is not a traditional CRO:<\/h2>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-4ae6af5 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"4ae6af5\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-19ed207 jltma-glass-effect-no\" data-id=\"19ed207\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a17dc7e jltma-glass-effect-no elementor-widget elementor-widget-text-editor\" data-id=\"a17dc7e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p>Dalriada is a leading Canadian contract research organization specialized in small molecule therapies. Purposely built as an agile, co-located and uniquely integrated drug discovery partner, Dalriada accelerates the discovery and development journey of high value new small molecule therapeutics from concept to PDC. Our partners have access to and support from a team of more than 60 drug discovery scientists (&gt;70% PhD) specialized across all aspects of medicinal &amp; computational chemistry, cell &amp; molecular biology, biophysics &amp; biochemistry, ADME and proteomics. Our unique Turn-Key\u2122 operational model offers the global biotechnology industry a full suite of drug discovery, preclinical development, intellectual property, and business expertise to manage and execute tailored R&amp;D programs. To date Dalriada has supported integrated programs of public andventure capital-backed companies, including Antibe, Janpix, Canopy Growth and Dunad Therapeutics.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Dalriada has worked with Dunad since its inception to support the development of its novel small molecule protein degradation modality<\/p>\n","protected":false},"author":2,"featured_media":852,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"post_folder":[],"_links":{"self":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts\/57"}],"collection":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/comments?post=57"}],"version-history":[{"count":4,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts\/57\/revisions"}],"predecessor-version":[{"id":7841,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/posts\/57\/revisions\/7841"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/media\/852"}],"wp:attachment":[{"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/media?parent=57"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/categories?post=57"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/tags?post=57"},{"taxonomy":"post_folder","embeddable":true,"href":"https:\/\/dalriadatx.com\/wp-json\/wp\/v2\/post_folder?post=57"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}